The therapeutic community is excited with anticipation surrounding retatrutide, a novel dual GIP and GLP-1 receptor that’s demonstrating significant promise in clinical trials for managing obesity. Unlike some available weight loss treatments, retatrutide appears to deliver a more substantial decrease in body size and improve metabolic health, p… Read More